Sign in →

Test Code CNEI Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation Interpretation, Serum (Non-Orderable)


Specimen Required


Only orderable as part of a profile. For more information see CNES / Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation, Serum.


Useful For

Only orderable as part of a profile. For more information see CNES / Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation, Serum.

 

Interpretation for the Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation

Method Name

Only orderable as part of a profile. For more information see CNES / Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation, Serum.

 

Technical Interpretation

Reporting Name

Comprehensive Neuropathy Interp, S

Specimen Type

Serum

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reference Values

Only orderable as part of a profile. For more information see CNES / Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation, Serum.

 

An interpretive report will be provided.

Interpretation

The presence of specific autoantibodies and/or combinations of antibodies in this panel provides supportive evidence of an immune-mediated peripheral neuropathy. However, these results must be interpretated in the appropriate clinical context. A negative result does not exclude the possibility of an immune mediated peripheral neuropathy.

Clinical Reference

1. Shelly S, Klein CJ, Dyck PJB, et al. Neurofascin-155 immunoglobulin subtypes: Clinicopathologic associations and neurologic outcomes. Neurology. 2021;97(24): e2392-e2403

2. Dubey D, Honorat JA, Shelly S, et al. Contactin-1 autoimmunity: Serologic, neurologic, and pathologic correlates. Neurol Neuroimmunol Neuroinflamm. 2020;7(4)e771

3. Paramasivan NK, Basal E, LaFrance-Corey RG, et al. Clinical Insights Into CASPR1 and CASPR1/contactin-1 complex autoimmune nodopathies. Neurology. 2026;106(5):e214403. doi:10.1212/WNL.0000000000214403

4. Klein CJ, Triplett JD, Murray DL, et al. Optimizing anti-myelin-associated glycoprotein and IgM-gammopathy testing for neuropathy treatment evaluation. Neurology. 2024;103(11):e210000. doi:10.1212/WNL.0000000000210000

5. Dubey D, Lennon VA, Gadoth A, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018;90(2):e103-e110. doi:10.1212/WNL.0000000000004803

6. Dubey D, Jitprapaikulsan J, Bi H, et al. Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome. Neurology. 2019;93(20):e1873-e1880. doi:10.1212/WNL.0000000000008472

7. Dubey D. Autoimmune neuromuscular disorders associated with neural antibodies. Continuum (Minneap Minn). 2024;30(4):1136-1159. doi:10.1212/CON.0000000000001461

Day(s) Performed

Monday through Sunday

Report Available

8 to 12 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

Not Applicable

LOINC Code Information

Result ID Test Result Name Result LOINC Value
621106 Comprehensive Neuropathy Interp, S 69048-7
624190 IFA Notes 48767-8